

# Ardeschir Ghofrani

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3367351/ardeschir-ghofrani-publications-by-citations.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

460 papers	40,487 citations	87 h-index	191 g-index
580 ext. papers	48,601 ext. citations	8.4 avg, IF	6.91 L-index

#	Paper	IF	Citations
460	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). <i>European Respiratory Journal</i> , <b>2015</b> , 46, 903-75	9.5	3455
459	Updated clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, D34-41	15.1	1937
458	Sildenafil citrate therapy for pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2148-57	59.2	1843
457	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). <i>European Respiratory Journal</i> , <b>2015</b> , 46, 903-75	13.6	1672
456	Inhaled iloprost for severe pulmonary hypertension. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 322-9	59.2	1308
455	Macitentan and morbidity and mortality in pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 809-18	59.2	878
454	Riociguat for the treatment of pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 330-40	59.2	861
453	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 319-29	59.2	852
452	Tadalafil therapy for pulmonary arterial hypertension. <i>Circulation</i> , <b>2009</b> , 119, 2894-903	16.7	769
451	Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. <i>Circulation</i> , <b>2008</b> , 117, 3010-9	16.7	769
450	Reversal of experimental pulmonary hypertension by PDGF inhibition. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 2811-21	15.9	764
449	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 834-44	59.2	618
448	Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. <i>Lancet, The</i> , <b>2002</b> , 360, 895-900	40	590
447	Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2522-33	59.2	521
446	Mechanisms of disease: pulmonary arterial hypertension. <i>Nature Reviews Cardiology</i> , <b>2011</b> , 8, 443-55	14.8	472
445	Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFIT (Bosentan Effects in iNoperable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 2127-34	15.1	409
444	Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 2546-52	15.1	393

443	Updated evidence-based treatment algorithm in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S78-S84	15.1	379
442	Imatinib for the treatment of pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1412-3	59.2	377
441	Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. <i>Circulation</i> , <b>2013</b> , 127, 1128-38	16.7	368
440	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. <i>Nature Reviews Drug Discovery</i> , <b>2006</b> , 5, 689-702	64.1	366
439	Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. <i>Annals of Internal Medicine</i> , <b>2002</b> , 136, 515-22	8	346
438	Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1999</b> , 160, 600-7	10.2	300
437	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 42, 158-64	15.1	290
436	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	288
435	Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. <i>Circulation Research</i> , <b>2007</b> , 101, 258-67	15.7	279
434	Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 182, 1171-7	10.2	276
433	Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. <i>Annals of Internal Medicine</i> , <b>1996</b> , 124, 820-4	8	273
432	Chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	263
431	Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 19093-8	11.5	247
430	A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 35, 176-82	15.1	246
429	Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). <i>Circulation</i> , <b>2014</b> , 129, 57-65	16.7	235
428	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 871-80	3.2	231
427	Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. <i>Cell</i> , <b>2011</b> , 147, 293-305	56.2	226
426	Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. <i>Annals of Internal Medicine</i> , <b>2004</b> , 141, 169-77	8	220

425	Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 897-908	10.2	219
424	Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. <i>Circulation</i> , <b>2013</b> , 128, 502-11	16.7	215
423	Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2003</b> , 167, 1139-41	10.2	211
422	Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 169, 39-45	10.2	207
421	Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 1971-81	15.1	191
420	Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. <i>Chest</i> , <b>2011</b> , 140, 1274-1283	5.3	187
419	Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 792-9	13.6	186
418	First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2009</b> , 33, 785-92	13.6	186
417	Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2008</b> , 32, 881-91	13.6	186
416	Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. <i>Circulation</i> , <b>2006</b> , 113, 286-95	16.7	183
415	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. <i>Nature Communications</i> , <b>2018</b> , 9, 1416	17.4	182
414	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). <i>European Respiratory Journal</i> , <b>2015</b> , 45, 1293-302	13.6	175
413	Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 185, 409-19	10.2	171
412	Sildenafil treatment for portopulmonary hypertension. <i>European Respiratory Journal</i> , <b>2006</b> , 28, 563-7	13.6	168
411	Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. <i>Circulation</i> , <b>2009</b> , 119, 1747-57	16.7	164
410	Safety and efficacy of exercise training in various forms of pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 84-92	13.6	158
409	Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. <i>Free Radical Biology and Medicine</i> , <b>2004</b> , 36, 1279-88	7.8	156
408	Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. <i>European Respiratory Journal</i> , <b>2008</b> , 32, 1639-51	13.6	152

407	2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2016</b> , 69, 177	0.7	148
406	Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1996</b> , 154, 57-62	10.2	147
405	A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. <i>Circulation</i> , <b>2009</b> , 119, 2313-22	16.7	146
404	Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. <i>FASEB Journal</i> , <b>2005</b> , 19, 1175-7	0.9	144
403	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 957-967	5.8	138
402	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , <b>2016</b> , 69, 177.e1-177.e62	1.5	137
401	Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. <i>Nature Communications</i> , <b>2012</b> , 3, 649	17.4	137
400	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 405-13	13.6	136
399	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 785-794	35.1	133
398	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). <i>European Respiratory Journal</i> , <b>2015</b> , 45, 1303-13	13.6	131
397	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , <b>2017</b> , 26,	9.8	130
396	Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 190, 808-17	10.2	129
395	Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2007</b> , 30, 922-7	13.6	127
394	Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 294-302	10.2	126
393	Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. <i>Respiration</i> , <b>2011</b> , 81, 394-401	3.7	125
392	Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. <i>Circulation</i> , <b>2008</b> , 118, 2081-90	16.7	121
391	Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. <i>Circulation</i> , <b>2007</b> , 115, 2331-9	16.7	118
390	Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 1672-81	15.1	115

389	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	111
388	Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 68S-72S	15.1	108
387	Targeting cancer with phosphodiesterase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , <b>2010</b> , 19, 117-31	5.9	105
386	Targeting non-malignant disorders with tyrosine kinase inhibitors. <i>Nature Reviews Drug Discovery</i> , <b>2010</b> , 9, 956-70	64.1	102
385	Prostacyclin and its analogues in the treatment of pulmonary hypertension <b>2004</b> , 102, 139-53		102
384	Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 768-74	15.1	101
383	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2008</b> , 32, 198-209	13.6	101
382	Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. <i>Chest</i> , <b>2003</b> , 124, 1294-304	5.3	100
381	Role of epidermal growth factor inhibition in experimental pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 158-67	10.2	99
380	Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 372-80	35.1	98
379	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1219-1227	2.4	96
378	Simvastatin as a treatment for pulmonary hypertension trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 1106-13	10.2	93
377	New trial designs and potential therapies for pulmonary artery hypertension. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, D82-91	15.1	90
376	Role of Src tyrosine kinases in experimental pulmonary hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2012</b> , 32, 1354-65	9.4	90
375	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. <i>PLoS ONE</i> , <b>2012</b> , 7, e43433	3.7	89
374	The molecular targets of approved treatments for pulmonary arterial hypertension. <i>Thorax</i> , <b>2016</b> , 71, 73-83	7.3	87
373	Pulmonary vascular disease in the developing world. <i>Circulation</i> , <b>2008</b> , 118, 1758-66	16.7	87
372	Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafertrine in chronic experimental pulmonary hypertension. <i>Circulation Research</i> , <b>2004</b> , 94, 1101-8	15.7	86



371	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 1488-96	15.1	86
370	Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2006</b> , 34, 505-13	5.7	83
369	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2011</b> , 30, 632-43	5.8	79
368	Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2001</b> , 17, 14-9	13.6	79
367	Effects of riociguat in severe experimental pulmonary hypertension. <i>BMC Pharmacology</i> , <b>2011</b> , 11,		78
366	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. <i>BMC Pharmacology</i> , <b>2011</b> , 11,		78
365	Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. <i>Circulation</i> , <b>2008</b> , 118, 1195-201	16.7	78
364	Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005512	7.6	78
363	Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , <b>2019</b> , 12, e009047	3.9	77
362	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 422-426	2.4	76
361	Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. <i>European Respiratory Journal</i> , <b>2011</b> , 37, 1104-18	13.6	75
360	Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H <sub>2</sub> O <sub>2</sub> ?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2000</b> , 279, L683-90	5.8	75
359	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	74
358	Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. <i>Molecular Biology of the Cell</i> , <b>2009</b> , 20, 4751-65	3.5	73
357	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 1366-75	5.8	72
356	Fhl-1, a new key protein in pulmonary hypertension. <i>Circulation</i> , <b>2008</b> , 118, 1183-94	16.7	71
355	Pathophysiology and treatment of high-altitude pulmonary vascular disease. <i>Circulation</i> , <b>2015</b> , 131, 582-90	16.7	70
354	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	70

353	Riociguat for the treatment of pulmonary hypertension. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 567-76	5.9	69
352	Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>1998</b> , 18, 479-88	5.7	69
351	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 361-71	35.1	69
350	Oleic acid inhibits alveolar fluid reabsorption: a role in acute respiratory distress syndrome?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 171, 469-79	10.2	68
349	Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1999</b> , 160, 1500-6	10.2	68
348	Nocturnal periodic breathing in primary pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2002</b> , 19, 658-63	13.6	67
347	Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 132-7	13.6	66
346	Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 188-96	10.2	66
345	Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , <b>2018</b> , 266, 229-235	3.2	65
344	Riociguat for pulmonary arterial hypertension associated with congenital heart disease. <i>Heart</i> , <b>2015</b> , 101, 1792-9	5.1	64
343	Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Respiratory Research</i> , <b>2013</b> , 14, 104	7.3	64
342	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 717-726	35.1	62
341	Novel and emerging therapies for pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 394-400	10.2	62
340	Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. <i>Critical Care Medicine</i> , <b>2002</b> , 30, 2489-92	1.4	62
339	Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. <i>Free Radical Biology and Medicine</i> , <b>2012</b> , 52, 1033-42	7.8	60
338	Inflammation, immunological reaction and role of infection in pulmonary hypertension. <i>Clinical Microbiology and Infection</i> , <b>2011</b> , 17, 7-14	9.5	60
337	Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 1359-73	10.2	59
336	Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 731-40	4.6	59



335	Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. <i>European Respiratory Journal</i> , <b>2007</b> , 29, 713-9	13.6	59
334	Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing. <i>Circulation Research</i> , <b>2017</b> , 121, 424-438	15.7	58
333	Sleep apnea in precapillary pulmonary hypertension. <i>Sleep Medicine</i> , <b>2013</b> , 14, 247-51	4.6	58
332	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	58
331	Classical transient receptor potential channel 1 in hypoxia-induced pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 188, 1451-9	10.2	58
330	Impairment of respiratory muscle function in pulmonary hypertension. <i>Clinical Science</i> , <b>2008</b> , 114, 165-76	16.5	58
329	Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2004</b> , 23, 321-6	13.6	58
328	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. <i>Chest</i> , <b>2017</b> , 151, 468-480	48.0	57
327	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 373-385	10.2	57
326	Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. <i>Antioxidants and Redox Signaling</i> , <b>2013</b> , 19, 2213-31	8.4	57
325	Effects of hypercapnia with and without acidosis on hypoxic pulmonary vasoconstriction. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2009</b> , 297, L977-83	5.8	57
324	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2008</b> , 21, 824-32	3.5	57
323	Pulmonary Hypertension. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2017</b> , 114, 73-84	2.5	57
322	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 1137-1149	13.6	57
321	Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na <sup>+</sup> ,K <sup>+</sup> -ATPase. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2005</b> , 33, 343-54	5.7	56
320	The lectin-like domain of tumor necrosis factor-alpha improves alveolar fluid balance in injured isolated rabbit lungs. <i>Critical Care Medicine</i> , <b>2008</b> , 36, 1543-50	1.4	55
319	Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 172, 358-63	10.2	55
318	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 227-238	35.1	55

317	Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. <i>Respiratory Research</i> , <b>2011</b> , 12, 60	7.3	53
316	NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2001</b> , 280, L638-45	5.8	53
315	PAR-2 inhibition reverses experimental pulmonary hypertension. <i>Circulation Research</i> , <b>2012</b> , 110, 1179-91	5.7	52
314	Basic features of hypoxic pulmonary vasoconstriction in mice. <i>Respiratory Physiology and Neurobiology</i> , <b>2004</b> , 139, 191-202	2.8	51
313	Mediator generation and signaling events in alveolar epithelial cells attacked by S. aureus alpha-toxin. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2002</b> , 282, L207-14	5.8	51
312	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 752-763	15.1	50
311	Mitochondrial hyperpolarization in pulmonary vascular remodeling. Mitochondrial uncoupling protein deficiency as disease model. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2013</b> , 49, 358-67	5.7	50
310	Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	50
309	The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 87ra53	17.5	50
308	Future perspectives for the treatment of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S108-S117	15.1	50
307	Effects of mitochondrial inhibitors and uncouplers on hypoxic vasoconstriction in rabbit lungs. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2003</b> , 29, 721-32	5.7	50
306	Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. <i>Intensive Care Medicine</i> , <b>1998</b> , 24, 631-4	14.5	49
305	Oxygen sensors in hypoxic pulmonary vasoconstriction. <i>Cardiovascular Research</i> , <b>2006</b> , 71, 620-9	9.9	49
304	Microcirculatory dysfunction in the brain precedes changes in evoked potentials in endotoxin-induced sepsis syndrome in rats. <i>Cerebrovascular Diseases</i> , <b>2007</b> , 23, 140-7	3.2	49
303	Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2001</b> , 164, 1694-700	10.2	49
302	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 482-9	12.3	49
301	p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2017</b> , 57, 603-614	5.7	48
300	5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. <i>BioMed Research International</i> , <b>2015</b> , 2015, 438403	3	48

299	Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , <b>2011</b> , 154 Suppl 1, S45-53	3.2	48
298	Cellular pathophysiology and therapy of pulmonary hypertension. <i>Translational Research</i> , <b>2001</b> , 138, 367-77		48
297	Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. <i>Respiratory Research</i> , <b>2011</b> , 12, 99	7.3	47
296	Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2010</b> , 49, 598-605	5.8	47
295	Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 38, 1130-6	15.1	47
294	Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. <i>Cerebrovascular Diseases</i> , <b>2006</b> , 21, 194-200	3.2	46
293	More on Single-Beat Estimation of Right Ventriculoarterial Coupling in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 816-818	10.2	45
292	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , <b>2017</b> , 38, 1147-1155	9.5	44
291	Diacylglycerol regulates acute hypoxic pulmonary vasoconstriction via TRPC6. <i>Respiratory Research</i> , <b>2011</b> , 12, 20	7.3	44
290	Amplified canonical transforming growth factor- $\beta$ signalling heat shock protein 90 in pulmonary fibrosis. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	43
289	Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 808-18	13.6	43
288	Effect of macitentan on hospitalizations: results from the SERAPHIN trial. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 1-8	7.9	42
287	miR-223-IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. <i>Cardiovascular Research</i> , <b>2016</b> , 111, 184-93	9.9	42
286	Current and future treatments of pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 6-30	8.6	42
285	Medical management of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , <b>2017</b> , 26,	9.8	41
284	Arterial hypertension in a murine model of sleep apnea: role of NADPH oxidase 2. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 300-5	1.9	41
283	Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. <i>European Respiratory Journal</i> , <b>2012</b> , 39, 119-24	13.6	41
282	Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0130072	3.7	41

281	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. <i>Nature Communications</i> , <b>2019</b> , 10, 2204	17.4	39
280	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. <i>American Journal of Cardiovascular Drugs</i> , <b>2018</b> , 18, 37-47	4	39
279	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893217753122	2.7	39
278	Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. <i>European Respiratory Journal</i> , <b>2009</b> , 33, 861-70	13.6	39
277	Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , <b>2011</b> , 154 Suppl 1, S20-33	3.2	38
276	The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. <i>European Journal of Clinical Investigation</i> , <b>2009</b> , 39 Suppl 2, 38-49	4.6	38
275	Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor- $\beta$ . <i>Pulmonary Circulation</i> , <b>2011</b> , 1, 259-68	2.7	38
274	Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. <i>European Respiratory Review</i> , <b>2009</b> , 18, 35-41	9.8	38
273	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 894-901	35.1	37
272	Cardiac Magnetic Resonance Imaging-Based Right Ventricular Strain Analysis for Assessment of Coupling and Diastolic Function in Pulmonary Hypertension. <i>JACC: Cardiovascular Imaging</i> , <b>2019</b> , 12, 2155-2164	8.4	36
271	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. <i>Chest</i> , <b>2017</b> , 151, 106-118	5.3	36
270	Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2009</b> , 22, 50-6	3.5	36
269	Hypoxia- and non-hypoxia-related pulmonary hypertension - established and new therapies. <i>Cardiovascular Research</i> , <b>2006</b> , 72, 30-40	9.9	36
268	Increased neutrophil mediator release in patients with pulmonary hypertension--suppression by inhaled iloprost. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 90, 1141-9	7	36
267	The role of combination therapy in managing pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2014</b> , 23, 469-75	9.8	35
266	Psoas muscle architectural design, in vivo sarcomere length range, and passive tensile properties support its role as a lumbar spine stabilizer. <i>Spine</i> , <b>2011</b> , 36, E1666-74	3.3	35
265	Burden of pulmonary arterial hypertension in Germany. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 902-10	4.6	34
264	Heme oxygenase-2 and large-conductance Ca <sup>2+</sup> -activated K <sup>+</sup> channels: lung vascular effects of hypoxia. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 180, 353-64	10.2	34

263	cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. <i>Circulation</i> , <b>2011</b> , 123, 1194-204	16.7	34
262	Pulmonary hypertension: updated classification and management of pulmonary hypertension. <i>Heart</i> , <b>2010</b> , 96, 552-9	5.1	34
261	Prostacyclin enhances stretch-induced surfactant secretion in alveolar epithelial type II cells. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1999</b> , 160, 846-51	10.2	34
260	Quality of life in patients with chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 526-37	13.6	34
259	Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. <i>Scientific Reports</i> , <b>2018</b> , 8, 1300	4.9	33
258	Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>1999</b> , 276, L90-5	5.8	33
257	Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. <i>PLoS ONE</i> , <b>2011</b> , 6, e18883	3.7	33
256	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , <b>2018</b> , 272S, 37-45	3.2	33
255	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2019</b> , 139, 2440-2450	16.7	32
254	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	32
253	The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2009</b> , 297, L658-65	5.8	32
252	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , <b>2018</b> , 18, 41	3.5	31
251	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1711-20	13.6	31
250	Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. <i>Respiratory Research</i> , <b>2007</b> , 8, 4	7.3	31
249	Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. <i>BMC Pulmonary Medicine</i> , <b>2008</b> , 8, 25	3.5	31
248	Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018783996	2.7	31
247	Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle. <i>Physiological Reports</i> , <b>2017</b> , 5, e13146	2.6	30
246	Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2018</b> ,	13.6	30

245	Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. <i>PLoS ONE</i> , <b>2011</b> , 6, e18136	3.7	30
244	Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2001</b> , 281, L1361-8	5.8	30
243	Evaluation and Prognostic Relevance of Right Ventricular-Arterial Coupling in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 116-119	10.2	30
242	Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1084-94	13.6	29
241	Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 42, 600-9	5.1	29
240	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2630-7	3.2	29
239	The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 707	8.4	29
238	New horizons in pulmonary arterial hypertension therapies. <i>European Respiratory Review</i> , <b>2013</b> , 22, 503-14	1.8	29
237	Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. <i>Respiratory Physiology and Neurobiology</i> , <b>2010</b> , 174, 282-91	2.8	29
236	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. <i>BMC Pulmonary Medicine</i> , <b>2010</b> , 10, 26	3.5	29
235	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. <i>Respiratory Research</i> , <b>2005</b> , 6, 128	7.3	29
234	Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2003</b> , 284, H931-8	5.2	29
233	Congenital erythropoietin over-expression causes "anti-pulmonary hypertensive" structural and functional changes in mice, both in normoxia and hypoxia. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 94, 630-8	7	29
232	Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	29
231	Mitochondrial cytochrome redox states and respiration in acute pulmonary oxygen sensing. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 1056-66	13.6	28
230	Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 1713-8	4.6	28
229	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. <i>Respiratory Physiology and Neurobiology</i> , <b>2007</b> , 159, 196-201	2.8	28
228	HbA1c in pulmonary arterial hypertension: a marker of prognostic relevance?. <i>Journal of Heart and Lung Transplantation</i> , <b>2012</b> , 31, 1109-14	5.8	27



227	Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. <i>Respiratory Research</i> , <b>2005</b> , 6, 86	7.3	27
226	Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension. <i>Annals of Internal Medicine</i> , <b>2006</b> , 144, 149-50	8	27
225	Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2000</b> , 161, 152-9	10.2	27
224	Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. <i>Pulmonary Circulation</i> , <b>2015</b> , 5, 296-304	2.7	26
223	Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. <i>Frontiers in Physiology</i> , <b>2018</b> , 9, 609	4.6	26
222	Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease. <i>Pulmonary Circulation</i> , <b>2014</b> , 4, 128-36	2.7	26
221	Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. <i>European Respiratory Journal</i> , <b>2008</b> , 31, 599-610	13.6	26
220	Endotoxin "priming" potentiates lung vascular abnormalities in response to Escherichia coli hemolysin: an example of synergism between endo- and exotoxin. <i>Journal of Experimental Medicine</i> , <b>1994</b> , 180, 1437-43	16.6	26
219	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 352-359	12.3	26
218	Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. <i>Respiratory Medicine</i> , <b>2017</b> , 128, 50-56	4.6	25
217	Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2014</b> , 306, L986-95	5.8	25
216	Dynamic hyperinflation during exercise in patients with precapillary pulmonary hypertension. <i>Respiratory Medicine</i> , <b>2012</b> , 106, 308-13	4.6	25
215	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. <i>Respiratory Research</i> , <b>2005</b> , 6, 76	7.3	25
214	Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 1407-1420	10.2	25
213	Riociguat for pulmonary hypertension. <i>Future Cardiology</i> , <b>2010</b> , 6, 155-66	1.3	24
212	Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide. <i>Respiratory Medicine</i> , <b>2007</b> , 101, 2125-32	4.6	24
211	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129327	3.7	24
210	A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. <i>Cancer Research</i> , <b>2007</b> , 67, 5443-53	10.1	23

209	Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2019</b> , 9, 2045894018803406	2.7	23
208	New potential diagnostic biomarkers for pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1390-6	13.6	22
207	Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 946-53	12.3	22
206	Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2000</b> , 23, 222-7	5.7	22
205	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 573-584	35.1	22
204	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 513-519	5.8	22
203	Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 20-37	2.7	21
202	Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). <i>Respiratory Research</i> , <b>2018</b> , 19, 258	7.3	21
201	Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	20
200	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. <i>International Journal of Cardiology</i> , <b>2016</b> , 216, 85-91	3.2	20
199	An evaluation of fracture stabilization comparing kyphoplasty and titanium mesh repair techniques for vertebral compression fractures: is bone cement necessary?. <i>Spine</i> , <b>2010</b> , 35, E768-73	3.3	20
198	Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2001</b> , 25, 219-25	5.7	20
197	Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. <i>European Respiratory Journal</i> , <b>2002</b> , 19, 664-71	13.6	20
196	Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 303, 741-5	4.7	20
195	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 720-727	7	20
194	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. <i>Heart</i> , <b>2017</b> , 103, 599-606	5.1	19
193	Sex Differences in Right Ventricular-Pulmonary Arterial Coupling in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 1042-1046	10.2	19
192	Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension. <i>Canadian Respiratory Journal</i> , <b>2017</b> , 2017, 8381653	2.1	19

191	Updating clinical endpoint definitions. <i>Pulmonary Circulation</i> , <b>2013</b> , 3, 206-16	2.7	19
190	Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2001</b> , 280, L896-904	5.8	19
189	Pulmonary Hemodynamic Response to Exercise in Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy. <i>Respiration</i> , <b>2015</b> , 90, 63-73	3.7	18
188	Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. <i>International Journal of Cardiology</i> , <b>2016</b> , 223, 821-826	3.2	18
187	Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2013</b> , 3, 523-32	2.7	18
186	Zardaverine and aerosolised iloprost in a model of acute respiratory failure. <i>European Respiratory Journal</i> , <b>2003</b> , 22, 342-7	13.6	18
185	Evaluation of the prognostic value of electrocardiography parameters and heart rhythm in patients with pulmonary hypertension. <i>Cardiology Journal</i> , <b>2016</b> , 23, 465-72	1.4	18
184	Right ventricular function correlates of right atrial strain in pulmonary hypertension: a combined cardiac magnetic resonance and conductance catheter study. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2020</b> , 318, H156-H164	5.2	18
183	Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. <i>Science Advances</i> , <b>2020</b> , 6, eaba0694	14.3	18
182	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. <i>American Journal of Human Genetics</i> , <b>2018</b> , 103, 144-153	11	18
181	Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. <i>Clinical Research in Cardiology</i> , <b>2017</b> , 106, 776-783	6.1	17
180	Short-term venoarterial extracorporeal membrane oxygenation for massive endobronchial hemorrhage after pulmonary endarterectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2018</b> , 155, 643-649	1.5	17
179	Impact of S-adenosylmethionine decarboxylase 1 on pulmonary vascular remodeling. <i>Circulation</i> , <b>2014</b> , 129, 1510-23	16.7	17
178	Effects of hypercapnia and NO synthase inhibition in sustained hypoxic pulmonary vasoconstriction. <i>Respiratory Research</i> , <b>2012</b> , 13, 7	7.3	17
177	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , <b>2010</b> , 11, 146	7.3	17
176	Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2009</b> , 296, L462-9	5.8	17
175	Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2011</b> , 1, 239-43	2.7	17
174	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , <b>2018</b> , 13, e0193226	3.7	17

173	Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 90-107	8.6	17
172	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. <i>BioMed Research International</i> , <b>2018</b> , 2018, 3293584	3	17
171	Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 509-519	5.8	16
170	Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. <i>Respiratory Research</i> , <b>2011</b> , 12, 87	7.3	16
169	A case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoïd therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 1196-8	10.2	16
168	Apical, but not basolateral, endotoxin preincubation protects alveolar epithelial cells against hydrogen peroxide-induced loss of barrier function: the role of nitric oxide synthesis. <i>Journal of Immunology</i> , <b>2002</b> , 169, 1474-81	5.3	16
167	Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 1235-1244	5.8	16
166	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	15
165	Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2013</b> , 49, 491-500	5.7	15
164	Cardiovascular Syndrome (Ortner's Syndrome) Associated with Chronic Thromboembolic Pulmonary Hypertension and Giant Pulmonary Artery Aneurysm: Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , <b>2012</b> , 2012, 230736	0.7	15
163	Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2001</b> , 280, L792-800	5.8	15
162	The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 505-513	2.7	14
161	Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice. <i>Experimental Physiology</i> , <b>2017</b> , 102, 180-189	2.4	14
160	A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	14
159	FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction. <i>Basic Research in Cardiology</i> , <b>2020</b> , 115, 17	11.8	14
158	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 836-843	5.8	14
157	Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/2 studies. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018769305	2.7	14
156	The prognostic impact of thyroid function in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, 1427-1434	5.8	14

155	Cofilin, a hypoxia-regulated protein in murine lungs identified by 2DE: role of the cytoskeletal protein cofilin in pulmonary hypertension. <i>Proteomics</i> , <b>2013</b> , 13, 75-88	4.8	14
154	Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. <i>Clinical Research in Cardiology</i> , <b>2017</b> , 106, 174-182	6.1	14
153	Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2019</b> , 60, 346-356	5.7	14
152	Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	13
151	Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 748-756	5.8	13
150	A simple echocardiographic estimate of right ventricular-arterial coupling to assess severity and outcome in pulmonary hypertension on chronic lung disease. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	13
149	Severe Emphysema in the SU5416/Hypoxia Rat Model of Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 515-518	10.2	13
148	Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2015</b> , 5, 305-12	2.7	13
147	Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2016</b> , 12, 63-8	6	13
146	Riociguat for pulmonary hypertension. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 2268	59.2	13
145	Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. <i>BMC Pulmonary Medicine</i> , <b>2011</b> , 11, 56	3.5	13
144	Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. <i>BMC Pharmacology</i> , <b>2009</b> , 9,		13
143	Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , <b>2006</b> , 19, 353-63		13
142	AMBRISANTAN HAS NO CLINICALLY RELEVANT EFFECT ON THE PHARMACOKINETICS OR PHARMACODYNAMICS OF WARFARIN. <i>Chest</i> , <b>2006</b> , 130, 256S	5.3	13
141	Increase in alveolar antioxidant levels in hyperoxic and anoxic ventilated rabbit lungs during ischemia. <i>Free Radical Biology and Medicine</i> , <b>2004</b> , 36, 78-89	7.8	13
140	Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?. <i>Histology and Histopathology</i> , <b>2013</b> , 28, 691-9	1.4	13
139	Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 667602	5	13
138	Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 1217-1227	9.9	12

137	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 401-408	5.8	12
136	The prognostic significance of inspiratory capacity in pulmonary arterial hypertension. <i>Respiration</i> , <b>2014</b> , 88, 24-30	3.7	12
135	Update on pulmonary hypertension 2009. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 1020-6	10.2	12
134	Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2015</b> , 5, 162-70	2.7	11
133	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 348-55	5.8	11
132	Nebulization of the acidified sodium nitrite formulation attenuates acute hypoxic pulmonary vasoconstriction. <i>Respiratory Research</i> , <b>2010</b> , 11, 81	7.3	11
131	Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 183-203	3.7	11
130	Nintedanib in Severe Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 808-810	10.2	11
129	Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 880-889	5.8	10
128	Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension. <i>Lung</i> , <b>2017</b> , 195, 489-496	2.9	10
127	A retrospective review of long anterior fusions to the sacrum. <i>Spine Journal</i> , <b>2011</b> , 11, 290-4	4	10
126	Stem cell-mediated natural tissue engineering. <i>Journal of Cellular and Molecular Medicine</i> , <b>2011</b> , 15, 52-63	3.6	10
125	2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. <i>Russian Journal of Cardiology</i> , <b>2016</b> , 5-64	1.3	10
124	Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Respiratory Medicine</i> , <b>2017</b> , 129, 124-129	4.6	9
123	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 338-47	5.8	9
122	Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , <b>2015</b> , 26, 155-62	0.8	9
121	Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension. <i>Frontiers in Pediatrics</i> , <b>2015</b> , 3, 63	3.4	9
120	Electrophysiological studies in patients with pulmonary hypertension: a retrospective investigation. <i>BioMed Research International</i> , <b>2014</b> , 2014, 617565	3	9



119	Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020941682	2.7	9
118	Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 194-202	5.8	9
117	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. <i>Respiratory Research</i> , <b>2019</b> , 20, 208	7.3	8
116	Right ventricular function in pulmonary (arterial) hypertension. <i>Herz</i> , <b>2019</b> , 44, 509-516	2.6	8
115	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	8
114	Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. <i>BMC Pulmonary Medicine</i> , <b>2016</b> , 16, 5	3.5	8
113	Animal models of pulmonary hypertension: role in translational research. <i>Drug Discovery Today: Disease Models</i> , <b>2010</b> , 7, 89-97	1.3	8
112	Synergism of alveolar endotoxin "priming" and intravascular exotoxin challenge in lung injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1996</b> , 154, 460-8	10.2	8
111	Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension. <i>Current Topics in Developmental Biology</i> , <b>2005</b> , 67, 251-84	5.3	8
110	The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152580	3.7	8
109	Modulating cGMP to treat lung diseases. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> , 469-83	3.2	8
108	Multibeat Right Ventricular-Arterial Coupling during a Positive Acute Vasoreactivity Test. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, e41-e42	10.2	8
107	Hypoxic Pulmonary Vasoconstriction Triggered by an Increase in Reactive Oxygen Species?. <i>Novartis Foundation Symposium</i> , 196-213		8
106	Resistant hypertension: medical management and alternative therapies. <i>Cardiology Clinics</i> , <b>2015</b> , 33, 75-87	2.5	7
105	Effects of carbon monoxide-releasing molecules on pulmonary vasoreactivity in isolated perfused lungs. <i>Journal of Applied Physiology</i> , <b>2016</b> , 120, 271-81	3.7	7
104	Enhanced circulating levels of CD3 cells-derived extracellular vesicles in different forms of pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2019</b> , 9, 2045894019864357	2.7	7
103	Measurement of exhaled hydrogen peroxide from rabbit lungs. <i>Biological Chemistry</i> , <b>2004</b> , 385, 259-64	4.5	7
102	Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study <b>2017</b> ,		7

101	COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	7
100	Association of right atrial conduit phase with right ventricular lusitropic function in pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , <b>2020</b> , 36, 633-642	2.5	7
99	Response by Tello et al to Letter Regarding Article, "Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension". <i>Circulation: Cardiovascular Imaging</i> , <b>2019</b> , 12, e010059	3.9	7
98	Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	7
97	Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels. <i>Experimental Physiology</i> , <b>2018</b> , 103, 1185-1191	2.4	7
96	Hypoxic pulmonary vasoconstriction--triggered by an increase in reactive oxygen species?. <i>Novartis Foundation Symposium</i> , <b>2006</b> , 272, 196-208; discussion 208-17		7
95	Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2014</b> , 28, 87-89	3.5	6
94	Subthreshold doses of nebulized prostacyclin and rolipram synergistically protect against lung ischemia-reperfusion. <i>Transplantation</i> , <b>2003</b> , 75, 814-21	1.8	6
93	Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. <i>Oncotarget</i> , <b>2017</b> , 8, 29613-29624	3.3	6
92	Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	6
91	Risk assessment in severe pulmonary hypertension due to interstitial lung disease. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 1118-1125	5.8	6
90	Prognostic Relevance of Nonsustained Ventricular Tachycardia in Patients with Pulmonary Hypertension. <i>BioMed Research International</i> , <b>2016</b> , 2016, 1327265	3	6
89	Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	6
88	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 720-7	7	6
87	The prognostic relevance of oxygen uptake in inoperable chronic thromboembolic pulmonary hypertension. <i>Clinical Respiratory Journal</i> , <b>2017</b> , 11, 682-690	1.7	5
86	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e005095	5.8	5
85	Altered proteasome function in right ventricular hypertrophy. <i>Cardiovascular Research</i> , <b>2020</b> , 116, 406-415	4.5	5
84	Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020910136	2.7	5

83	Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165982	3.7	5
82	Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020961739	2.7	5
81	Relevance of angiopoietin-2 and soluble P-selectin levels in patients with pulmonary arterial hypertension receiving combination therapy with oral treprostinil: a FREEDOM-C2 biomarker substudy. <i>Pulmonary Circulation</i> , <b>2016</b> , 6, 516-523	2.7	5
80	Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. <i>Circulation: Cardiovascular Imaging</i> , <b>2018</b> , 11, e007653	3.9	5
79	Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension. <i>BMC Pulmonary Medicine</i> , <b>2015</b> , 15, 11	3.5	4
78	Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
77	Evaluation of pulmonary hypertension by right heart catheterisation: does timing matter?. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	4
76	Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice. <i>Respiratory Research</i> , <b>2020</b> , 21, 136	7.3	4
75	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. <i>Nature Metabolism</i> , <b>2020</b> , 2, 532-546	14.6	4
74	Cytochrome P450 epoxygenase-derived 5,6-epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. <i>Acta Physiologica</i> , <b>2020</b> , 230, e13521	5.6	4
73	Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018798921	2.7	4
72	Reply to Bogaard : Emphysema Is-at the Most-Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1450-1452	10.2	4
71	Long-term Riociguat Treatment in Inoperable and Persistent/Recurrent CTEPH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 16-Week Phase III CHEST-1 Study and CHEST-2 Open-Label Extension. <i>Chest</i> , <b>2014</b> , 145, 535B	5.3	4
70	Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". <i>Circulation</i> , <b>2014</b> , 130, e110-2	16.7	4
69	Cologne Consensus Conference on pulmonary hypertension. <i>International Journal of Cardiology</i> , <b>2011</b> , 154 Suppl 1, S1-2	3.2	4
68	Right ventricular pressure-volume loop shape and systolic pressure change in pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2021</b> , 320, L715-L725	5.8	4
67	Impact of SARS-CoV-2-Pandemic on Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 668647	5	4
66	Heart rate response during 6-minute walking testing predicts outcome in operable chronic thromboembolic pulmonary hypertension. <i>BMC Pulmonary Medicine</i> , <b>2016</b> , 16, 96	3.5	4

65	COPD-associated pulmonary hypertension: clinical implications and current methods for treatment. <i>Expert Review of Respiratory Medicine</i> , <b>2016</b> , 10, 755-66	3.8	4
64	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 51	5.4	4
63	Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study. <i>Respiratory Medicine</i> , <b>2017</b> , 132, 50-55	4.6	3
62	Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population. <i>Frontiers in Physiology</i> , <b>2019</b> , 10, 54	4.6	3
61	Right ventricular dyssynchrony: from load-independent right ventricular function to wall stress in severe pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020925759	2.7	3
60	Measures of subclinical cardiac dysfunction and increased filling pressures associate with pulmonary arterial pressure in the general population: results from the population-based Rotterdam Study. <i>European Journal of Epidemiology</i> , <b>2018</b> , 33, 403-413	12.1	3
59	Acute response to rapid iloprost inhalation using the Breelib <sup>®</sup> nebulizer in pulmonary arterial hypertension: the Breelib <sup>®</sup> acute study. <i>Pulmonary Circulation</i> , <b>2019</b> , 9, 2045894019875342	2.7	3
58	Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension. <i>Chest</i> , <b>2014</b> , 145, 513A	5.3	3
57	Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH). <i>Chest</i> , <b>2015</b> , 148, 961A	5.3	3
56	Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study. <i>Chest</i> , <b>2013</b> , 144, 1024A	5.3	3
55	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): 1-Year Results from the CHEST-2 Long-term Extension Study. <i>Chest</i> , <b>2013</b> , 144, 1023A	5.3	3
54	Diagnostik und Therapie der pulmonalen Hypertonie. <i>Kardiologe</i> , <b>2010</b> , 4, 189-207	0.6	3
53	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled servalutinib for the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211057071	2.7	3
52	Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. <i>EClinicalMedicine</i> , <b>2021</b> , 34, 100822	11.3	3
51	Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. <i>Blood</i> , <b>2021</b> , 137, 2681-2693	2.2	3
50	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	3
49	A novel non-invasive and echocardiography-derived method for quantification of right ventricular pressure-volume loops. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2021</b> ,	4.1	3
48	Inspiratory capacity is not altered in operable chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 543-546	2.7	2

47	Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1550-1554	10.2	2
46	Pulmonary Vascular Pressure Response to Acute Cold Exposure in Kyrgyz Highlanders. <i>High Altitude Medicine and Biology</i> , <b>2019</b> , 20, 375-382	1.9	2
45	Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, S163	5.8	2
44	Genetic Deletion of p66shc and/or Cyclophilin D Results in Decreased Pulmonary Vascular Tone. <i>Cardiovascular Research</i> , <b>2020</b> ,	9.9	2
43	Beyond interleukin-6 in right ventricular function: Evidence for another biomarker. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 674-675	5.8	2
42	Riociguat in Combination With Prostacyclin Analogs for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of the PATENT Studies. <i>Chest</i> , <b>2015</b> , 148, 922A	5.3	2
41	Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH). <i>BMC Pharmacology</i> , <b>2009</b> , 9,		2
40	Effects Of Inhaled Aviptadil (Vasoactive Intestinal Peptide) In Patients With Pulmonary Arterial Hypertension (PAH) <b>2010</b> ,		2
39	Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population <b>2015</b> ,		2
38	IRAG1 Deficient Mice Develop PKG1-Dependent Pulmonary Hypertension. <i>Cells</i> , <b>2020</b> , 9,	7.9	2
37	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020947283	3.7	2
36	Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	2
35	Selexipag for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1825-34	4	2
34	Amelioration of elastase-induced lung emphysema and reversal of pulmonary hypertension by pharmacological iNOS inhibition in mice. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 152-171	8.6	2
33	Prevalence of Mental Disorders in Patients With Chronic Thromboembolic Pulmonary Hypertension.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 821466	5	2
32	Cardiopulmonary haemodynamics in portopulmonary hypertension. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 556-558	35.1	1
31	Reply to "a pediatric perspective on the TAPSE/PASP ratio in pulmonary arterial hypertension". <i>International Journal of Cardiology</i> , <b>2019</b> , 278, 240-241	3.2	1
30	is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties. <i>Medicina (Lithuania)</i> , <b>2020</b> , 56,	3.1	1

29	SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension. <i>Biomarkers</i> , <b>2020</b> , 25, 290-295	2.6	1
28	Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study.. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 781532	5	1
27	Clinical Relevance of Right Atrial Functional Response to Treatment in Pulmonary Arterial Hypertension.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 775039	5.4	1
26	Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 191-193	35.1	1
25	EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. <i>Pulmonary Circulation</i> , <b>2019</b> , 2045894019837849	2.7	1
24	PINK1-mediated Mitophagy Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2021</b> , 65, 226-228	5.7	1
23	Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodeling in pulmonary hypertension. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 1021-1034	2.3	1
22	Exercise Hemodynamic Profiling Is Associated With Outcome in Patients Undergoing Percutaneous Mitral Valve Repair. <i>Circulation: Cardiovascular Interventions</i> , <b>2021</b> , 14, e010453	6	1
21	Phosphodiesterase-5 Inhibitors in Pulmonary Arterial Hypertension	105-125	1
20	Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 821468	5	1
19	Follow-Up (Measurement) of Corrected QT Interval in Adult Patients before and after Lung Transplantation. <i>BioMed Research International</i> , <b>2017</b> , 2017, 4519796	3	0
18	Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009. <i>Deutsche Medizinische Wochenschrift</i> , <b>2010</b> , 135, e2-e15	0	0
17	Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	0
16	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2021</b> , 11, 1255-1268	2.6	0
15	Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 826369	5.4	0
14	Tidal Carbon Dioxide as a Prognostic Feature in Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , <b>2017</b> , 14, 1603-1604	4.7	
13	Therapie der pulmonal arteriellen Hypertonie. <i>Kliniker</i> , <b>2017</b> , 46, 374-381	0	
12	Aktuelle Therapie der pulmonal-arteriellen Hypertonie. <i>Pneumologie</i> , <b>2010</b> , 7, 192-199	0.1	



11	Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure. <i>European Respiratory Review</i> , <b>2008</b> , 17, 72-73	9.8
10	Sildenafil for lung fibrosis and pulmonary hypertension. <i>Lancet, The</i> , <b>2003</b> , 361, 263	4.0
9	Schwere pulmonale Hypertonie - Vasodilative Therapie in der Lungenstrombahn. <i>Pneumologie</i> , <b>2000</b> , 54, 160-169	0.5
8	Childhood Trauma in Patients With PAH-Prevalence, Impact on QoL, and Mental Health-A Preliminary Report.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 812862	5
7	NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension <b>2004</b> , 163-168	
6	Classical transient receptor potential channel 6 (TRPC6) is essential for ischemia-reperfusion injury of the lung. <i>FASEB Journal</i> , <b>2010</b> , 24, 591.2	0.9
5	Pulmonalarterielle Hypertonie bei angeborenen Herzfehlern: Problemstellung und Versorgungslage. <i>Deutsche Medizinische Wochenschrift</i> , <b>2013</b> , 138, e27-e27	0
4	Reply to "Risk stratification in PH associated with interstitial lung disease: The Holy Grail?". <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 317	5.8
3	Response to: Comment on "Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding". <i>BioMed Research International</i> , <b>2018</b> , 2018, 7491284	3
2	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. <i>Communications Biology</i> , <b>2021</b> , 4, 1002	6.7
1	Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial Hypertension.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 812812	5